Grifols (GRFS) EPS (Basic) Growth (3y) (2013 - 2020)
Grifols (GRFS) EPS (Basic) Growth (3y) (2013 - 2020) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.66 Bn | 632.90 Bn | 17.26 Bn | 5.11% |
| 2 | AbbVie | 470.02 Bn | 463.46 Bn | 12.70 Bn | 21.23% |
| 3 | Merck | 379.06 Bn | 371.92 Bn | 12.21 Bn | 38.72% |
| 4 | Novartis Ag | 302.95 Bn | 295.26 Bn | 11.24 Bn | -59.02% |
| 5 | Astrazeneca | 257.68 Bn | 252.78 Bn | 12.86 Bn | 11.28% |
| 6 | Amgen | 236.97 Bn | 222.98 Bn | 7.24 Bn | 19.50% |
| 7 | Gilead Sciences | 182.78 Bn | 179.60 Bn | 6.22 Bn | -129.90% |
| 8 | Pfizer | 161.51 Bn | 149.81 Bn | 10.94 Bn | -28.08% |
| 9 | Gsk | 105.54 Bn | 101.37 Bn | 8.24 Bn | -34.06% |
| 10 | Grifols | 5.51 Bn | 4.51 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 9.92% |
| Dec 31, 2019 | 69.99% |
| Mar 31, 2019 | -20.10% |
| Dec 31, 2018 | 77.56% |
| Jun 30, 2018 | 21.09% |
| Mar 31, 2018 | 22.15% |
| Dec 31, 2017 | 14.57% |
| Jun 30, 2017 | -6.24% |
| Mar 31, 2017 | 14.23% |
| Dec 31, 2016 | -31.68% |
| Sep 30, 2016 | 12.41% |
| Jun 30, 2016 | 19.27% |
| Mar 31, 2016 | 47.09% |
| Dec 31, 2015 | -24.46% |
| Sep 30, 2015 | 20.61% |
| Jun 30, 2015 | 15.95% |
| Mar 31, 2015 | 13.80% |
| Dec 31, 2014 | 297.45% |
| Sep 30, 2014 | 114.39% |
| Jun 30, 2014 | 137.17% |